Phathom outlines $320M-$345M 2026 revenue guidance as company targets operating profitability
Source: SeekingAlpha
2026-02-26 17:10:22 ET
More on Phathom Pharmaceuticals
- Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
- Phathom: Why I'm Not Buying The Dip (Yet)
- Phathom Pharmaceuticals Non-GAAP EPS of -$0.08 beats by $0.11, revenue of $57.6M beats by $0.16M
- Phathom Pharmaceuticals Q4 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Phathom outlines $320M–$345M 2026 revenue guidance as company targets operating profitability
Phathom Pharmaceuticals Inc.
NASDAQ: PHAT
PHAT Trading
-6.09% G/L:
$10.33 Last:
416,386 Volume:
$10.46 Open:
PHAT Latest News
February 26, 2026 07:00:00 am
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
PHAT Stock Data
$1,007,653,754
60,286,977
0.48%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Florham Park
